Scilex Holding (SCLX) Total Current Liabilities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Total Current Liabilities of $501.8 million for Q1 2026, up 81.96% year-over-year from $275.7 million in Q1 2025, and up 3.74% quarter-over-quarter from $483.7 million in Q4 2025.
Scilex Holding (SCLX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $501.8 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 81.96% year-over-year to $501.8 million; the TTM figure through Mar 2026 stood at $501.8 million (up 81.96% YoY), while the FY2025 annual figure was $483.7 million, up 86.28% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $501.8 million, up from $483.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $501.8 million in Q1 2026, with the low at $41003.0 in Q1 2022.
- The 5-year median for Total Current Liabilities is $252.7 million (2024), against an average of $215.8 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities sank 73.53% in 2022, then jumped 157454.33% in 2023.
- Scilex Holding's Total Current Liabilities stood at $44.8 million in 2022, then soared by 458.36% to $250.4 million in 2023, then advanced by 3.7% to $259.6 million in 2024, then surged by 86.28% to $483.7 million in 2025, then increased by 3.74% to $501.8 million in 2026.
- Business Quant data shows SCLX's Total Current Liabilities at $501.8 million in Q1 2026, $483.7 million in Q4 2025, and $358.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.91 Bn | 632.15 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 469.40 Bn | 462.83 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 375.75 Bn | 368.61 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.13 Bn | 295.44 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 257.65 Bn | 252.75 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 236.26 Bn | 222.27 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 182.12 Bn | 178.95 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.21 Bn | 102.04 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Scilex Holding | 39.10 Mn | -73.69 Mn | 3.97 Mn | 512.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 501.75 Mn |
| Dec 31, 2025 | 483.65 Mn |
| Sep 30, 2025 | 358.95 Mn |
| Jun 30, 2025 | 305.93 Mn |
| Mar 31, 2025 | 275.74 Mn |
| Dec 31, 2024 | 259.64 Mn |
| Sep 30, 2024 | 281.54 Mn |
| Jun 30, 2024 | 255.45 Mn |
| Mar 31, 2024 | 252.73 Mn |
| Dec 31, 2023 | 250.38 Mn |
| Sep 30, 2023 | 228.58 Mn |
| Jun 30, 2023 | 103.58 Mn |
| Mar 31, 2023 | 64.60 Mn |
| Dec 31, 2022 | 44.84 Mn |
| Sep 30, 2022 | 809,292.00 |
| Jun 30, 2022 | 598,646.00 |
| Mar 31, 2022 | 41,003.00 |
| Dec 31, 2021 | 169.42 Mn |
| Sep 30, 2021 | 43,569.00 |
| Jun 30, 2021 | 20,025.00 |